Happy Thursday. Here's what the Zen Ratings are charging up and powering down today:
P.S. Speaking of hot news, did you hear that Michael Burry shorted Micron? Get the story here.
A note from our sponsors...
Bitcoin Got the Idea Right. It Got the Backing Wrong.
Bitcoin proved millions want money no government can print. But it's backed by nothing but belief.
What happens when you keep everything it got right — and back it with real, verified gold? You find out July 8.
🔥 HOT: Medical distribution heavyweight Cardinal Health (CAH) is showing that steady healthcare infrastructure can outrun the market. The company delivers pharmaceuticals and medical supplies to roughly 75% of U.S. hospitals, and it's building new profit streams on top of that base. Wall Street likes what it sees: 8 of 9 covering analysts recommend CAH a Strong Buy or Buy.
The ratings support the optimism. CAH holds an A Zen Rating, which amounts to a Strong Buy recommendation. On top of that, it ranks #1 in the A-rated Medical Distribution industry. Its component profile combines an A for Sentiment with B grades for Growth and Safety — strong analyst conviction, forecast earnings growth above 30% per year, and the defensive resilience healthcare is known for. That mix of expansion and dependability puts Cardinal Health in a rare company among large-cap healthcare names.
🥶 NOT: Tempus AI (TEM) is losing steam after a powerful run earlier this year. Shares have pulled back sharply as investors lock in gains, and the company has yet to deliver a meaningful new catalyst to reignite momentum. At the same time, enthusiasm around AI-driven drug discovery and healthcare platforms has cooled across the sector, making investors more selective.
That weakness is reflected in its recent Zen Rating downgrade to a D (Sell recommendation) with D grades for Financials, Momentum, Safety, Sentiment, and AI. Until Tempus can rebuild momentum and demonstrate stronger execution, there are better opportunities elsewhere in the market.
🔥 HOT: Industrial battery specialist EnerSys (ENS) is plugged directly into the AI data center boom. The company’s Q4 earnings and sales both topped estimates and grew year-over-year, while insiders have been net buyers over the past 12 months — a signal of genuine internal confidence. After reaching a 52-week high, the stock has retreated, potentially offering a better entry into an unchanged growth story.
The Zen Ratings back up the “buy the dip” thesis. ENS earns an A Zen Rating, ranking in the elite top 5% of the 4600+ stocks we track. Its Component Grade mix is one of the strongest in the "hot" pool: an A for Financials plus B grades across Value, Momentum, Sentiment, Safety, and AI. That combination signals a company with rock-solid financial health, reasonable valuation for its growth profile, and momentum that Wall Street's smart money is quietly backing. That consistency makes EnerSys one of the more attractive overlooked names in the Electrical Equipment space.
🥶 NOT: Quantum computing hopeful Infleqtion (INFQ) can't convert headlines into shareholder value. The neutral-atom quantum technology company rallied earlier this year on a favorable Executive Order on Quantum Technology and a $100 million CHIPS funding letter of intent, but the gains have evaporated — the stock is down about 20% in the past month. Insider activity adds to the concern: the CTO and multiple directors sold over $30 million in stock in late May alone, while the company posted losses of $62 million and a profit margin near negative 148%
The Zen Ratings tell the same story as the insiders. INFQ earns a D Zen Rating, placing it firmly in the "Sell" tier, and it ranks a weak #115 of 128 in the Software Infrastructure industry. The Component Grades show broad weakness — D grades for Value, Safety, Financials, and AI point to a company with fragile fundamentals across nearly every dimension the model tracks. The quantum theme will keep drawing attention, but with this much insider selling and this little profitability, INFQ remains a stock to admire from a distance rather than own.
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.